Online inquiry

IVTScrip™ mRNA-Anti-RGMA, ABT-555(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1295MR)

This product GTTS-WQ1295MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets RGMA gene. The antibody can be applied in Multiple sclerosis (MS) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001166283.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 56963
UniProt ID Q96B86
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-RGMA, ABT-555(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ1295MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7259MR IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FP3 protein
GTTS-WQ13321MR IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PF-06741086
GTTS-WQ4366MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-188667
GTTS-WQ11335MR IVTScrip™ mRNA-Anti-F, MEDI-524(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MEDI-524
GTTS-WQ8860MR IVTScrip™ mRNA-Anti-MS4A1, IDEC-C2B8(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IDEC-C2B8
GTTS-WQ11338MR IVTScrip™ mRNA-Anti-F, MEDI-524(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MEDI-524
GTTS-WQ10879MR IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MAb-14.18
GTTS-WQ11141MR IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MDX-1103
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW